Sageworth Trust Co Has $711,000 Position in Merck & Co., Inc. (NYSE:MRK)

Sageworth Trust Co increased its position in Merck & Co., Inc. (NYSE:MRK) by 838.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,475 shares of the company’s stock after buying an additional 7,572 shares during the period. Merck & Co., Inc. accounts for 0.1% of Sageworth Trust Co’s portfolio, making the stock its 29th largest holding. Sageworth Trust Co’s holdings in Merck & Co., Inc. were worth $711,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in MRK. Oregon Public Employees Retirement Fund increased its holdings in Merck & Co., Inc. by 17,936.7% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 53,150,490 shares of the company’s stock worth $696,000 after buying an additional 52,855,811 shares during the last quarter. Norges Bank acquired a new position in Merck & Co., Inc. in the fourth quarter worth approximately $2,166,688,000. Jennison Associates LLC increased its holdings in Merck & Co., Inc. by 323.1% in the fourth quarter. Jennison Associates LLC now owns 15,777,286 shares of the company’s stock worth $1,205,542,000 after buying an additional 12,048,406 shares during the last quarter. BlackRock Inc. boosted its position in Merck & Co., Inc. by 5.6% during the fourth quarter. BlackRock Inc. now owns 194,589,541 shares of the company’s stock worth $14,868,587,000 after purchasing an additional 10,315,510 shares during the period. Finally, FMR LLC boosted its position in Merck & Co., Inc. by 41.2% during the first quarter. FMR LLC now owns 11,111,444 shares of the company’s stock worth $924,139,000 after purchasing an additional 3,244,078 shares during the period. Hedge funds and other institutional investors own 75.15% of the company’s stock.

In other news, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total value of $18,514,218.74. Following the completion of the sale, the chief financial officer now directly owns 354,378 shares of the company’s stock, valued at $30,274,512.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Frank Clyburn sold 25,000 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $77.73, for a total value of $1,943,250.00. Following the completion of the sale, the executive vice president now directly owns 92,604 shares of the company’s stock, valued at $7,198,108.92. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by corporate insiders.

Shares of MRK traded up $0.78 during mid-day trading on Friday, hitting $84.47. The company’s stock had a trading volume of 10,413,945 shares, compared to its average volume of 9,795,701. Merck & Co., Inc. has a one year low of $64.97 and a one year high of $87.07. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a market capitalization of $213.67 billion, a price-to-earnings ratio of 19.46, a PEG ratio of 1.70 and a beta of 0.56. The business has a 50-day moving average of $83.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a return on equity of 42.84% and a net margin of 21.10%. The company had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $10.94 billion. During the same period in the prior year, the business earned $1.06 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 12.4% compared to the same quarter last year. Research analysts expect that Merck & Co., Inc. will post 4.93 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Stockholders of record on Monday, September 16th will be given a $0.55 dividend. The ex-dividend date is Friday, September 13th. This represents a $2.20 annualized dividend and a dividend yield of 2.60%. Merck & Co., Inc.’s dividend payout ratio is 50.69%.

A number of equities research analysts have issued reports on the company. Citigroup upped their target price on Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. They noted that the move was a valuation call. Atlantic Securities raised Merck & Co., Inc. from a “neutral” rating to an “overweight” rating in a research report on Monday, May 13th. They noted that the move was a valuation call. Credit Suisse Group assumed coverage on Merck & Co., Inc. in a research report on Thursday, July 11th. They set a “buy” rating and a $95.00 target price for the company. Morgan Stanley upped their target price on Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, June 21st. Finally, UBS Group upped their target price on Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $90.36.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: CBOE Russell 2000® Volatility Index

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.